34 billion antithrombotic drugs market hit! TOP10 products are out.

By the impact of collection, "anti-thrombosis one brother" clopidogrel market size has declinedAnd according to the spread of the third batch of collection list, for Grillo, Apixaban in the list, anti-thrombosis drug market further pressure! According to Minet.com, sales of antithrombotic drugs at the end of Public Medical Institutions in China in 2019 were 34.337 billion yuan, a growth rate of less than 10% for the first timeAt present, antithrombotic drugs have 7 varieties (25 standards) have been evaluated, zhengda sunny involving 5, stone drug Europa 3, Xinlitai, Qilu Pharmaceuticals each have 2With the normalization of band purchase, the profitability of generic drugs declined, a number of pharmaceutical companies have begun to develop anti-thrombotic drugs, Hengrui, Shanghai, China Resources and other 5 enterprises anti-thrombotic class 1 new drugs have submitted for clinical trial applications, China's biopharmaceutical subsidiary Nanjing Zhengda Qing's sulphate clopipidogrere tablet (75mg) was approved by the State Drug Administration for listing, becoming the fourth domestic company of the species to be approved for listingWith the addition of Nanjing Zhengda Qing, the current domestic sulphuric acid chloride pipropramy tablet manufacturers a total of 6, forming 4 domestic and 3 foreign enterprises in the competitive patternhydrogen sulphate clopidogrel tablets, the leading varieties in the antithrombotic drug market, have been included in the first batch of collectionAccording to Minet.com, sales of hydrogen sulphate clopidore tablets at public medical institutions in China fell to 11.572 billion yuan in 2019, down 5.45 percent year-on-year, driven by the "4 plus 7" collection price reductionit is worth mentioning that with the approval of clopidogrel and treated as if it were reviewed, China Biopharma has five antithrombotic drugs through consistency evaluationThe database of the consistency evaluation of the inner net shows that there are currently 7 varieties (25 standards) of antithrombotic drugsAmong them, China Biopharmaceutical Group to 5 varieties to lead, stone medicine European meaning has 3 varieties have been evaluated, Xinlitai, Qilu Pharmaceuticals have 2 varieties have been evaluatedantithrombotic drug consistency evaluation through the situation
cardiovascular medication is a major important category of the domestic hospital drug market, which is also the first antithrombotic drugThe first batch of collection varieties will be "anti-thrombosis one brother" clopidogrerel included, the second batch of collection varieties no antithrombotic drugs were included, the third batch of collection varieties will soon be officially announced, according to the circulating list, for Grillo tablets (90mg), apixaban tablets (2.5mg) in the columnAt present for the Greilo film review enterprises up to 7, Apixaban review enterprises up to 4, a fierce price war is inevitable, sales of antithrombotic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions) in 2019 were 34.337 billion yuan, up 9% year-on-year, according to.S.S.A The growth rate of antithrombotic drug sales in 2019 was less than 10% for the first time in 2019, influenced by policies such as health insurance control fees, rational drug use and volume purchase China's public medical institutions terminal antithrombotic drug sales (units: 10,000 yuan) in anti-thrombosis drug products TOP10, 7 productsales of more than 1 billion yuan, hydrogen sulfate chloride pipropramy tablets with sales of 11.572 billion yuan ranked first, the second-ranked defa sand sand tablet sales of 2.506 billion yuan, there is still huge growth In terms of sales growth rate, the first decline in the sulphate clopidogrerere tablets, low molecular weight heparin calcium injections, the sales growth rate of clopidogrel slowed year by year, from 19.5% in 2014 to -5.45% in 2019; 2019 China's public medical institutions terminal antithrombotic drug products TOP10 antithrombotic drug brand TOP10, 8 brands sales of more than 1 billion yuan, Sanofi, Xinlita, Lepu Pharmaceuticals 3 pharmaceutical companies of the sulphate hydropropyrisnogram tablets are on the list Sanofi has two brands on the list, Bolevi (hydrosulphate clopidogrel tablets) and Kesai (enochparin sodium injection) AstraZeneca's sales of its DeGrillo films rose 45.36 percent, while Bayer's Delavsaban rose 41.52 percent Although Zhengda Tianqing Pharmaceutical Group, Stone Pharmaceuticals Oyi has won the production approval of TheLeva Saban, but the domestic Leva saban film is still exclusive by the original research Bayer, its original compound patent will expire in December 2020 This is also the main reason why the Devandsaban film was not included in the third batch of collection 2019 China's public medical institutions terminal antithrombotic drug brand TOP10 With the normalization of national drug volume procurement, more and more antithrombotic drugs will be included in the procurement scope The profitability of generic drugs declined, and a number of pharmaceutical companies pre-empted the development of new antithrombotic drugs June 23, Shanghai Pharma announced that the company's application for the LT3001 clinical trial was accepted by the State Drug Administration, the acceptance number is JXHL2000142; The LT3001 is the world's first innovative stroke treatment program combining targeted thrombosis and cerebral nerve protection, and has now launched Phase II clinical trials in the United States and Taiwan is unique, Hengrui Pharmaceuticals anti-thrombotic new drugs have also made new progress On June 24, Hengrui Pharmaceuticals announced that the State Drug Administration agreed to the company's SHR2285 pharmaceutical changes and conduct Phase I clinical trials in accordance with the proposed plan SHR2285 tablets are intended to be used to prevent or treat thrombosis in the veins and to reduce the risk of thromboembolism caused by interventional therapy or in vitro circulation At present, similar products are in the clinical trial stage, no similar products at home and abroad have been approved for listing -meter net data show that there are currently 5 anti-thrombotic class 1 new drug submitted clinical trial applications Xi'an Yangsen's JNJ-70033093 capsules and Hengrui Pharma's SHR2285 tablets have been implicitly licensed for clinical trials China Resources Ond Bio's recombinant human tissue-type lysozyme kinase derivative (Rui Tongli) has been approved earlier for treatment of acute myocardial infarction, 2019 into the national health insurance negotiation strucination directory; The market size of the drug is expected to rise with the approval of new indications the development of a new type 1 drug to fight thrombosis is Original title: 34 billion antithrombotic drugs market hit! TOP10 products out, HengRui, medicine, China Resources .. Attack class 1 new drugs.